South & Central America Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)
The South & Central America human vaccine adjuvants market was valued at US$ 63.62 million in 2022 and is expected to reach US$ 185.34 million by 2030; it is estimated to register a CAGR of 14.3% from 2022 to 2030.
Rising Trend of Personalized Vaccines Fuels South & Central America Human Vaccine Adjuvants MarketPrecision or personalized vaccines are a growing trend in the South & Central America human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders. Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the South & Central America human vaccine adjuvants market.
South & Central America Human Vaccine Adjuvants Market OverviewBrazil is among the largest countries in South & Central America. According to the Brazilian Institute of Geography and Statistics (IBGE), Brazil has a unified healthcare system (SUS) that caters health services to approximately 72% of the population. SUS provides free medication and promotes national vaccination programs mostly focused on older adults and children. According to the International Trade Administration, Brazilian public laboratories and universities play a key role in research and development for diagnostic kits, drugs, and vaccines.
According to the Global Burden of Disease study published in October 2020, Brazil has an increasing prevalence of various chronic and infectious diseases, such as tuberculosis, stroke, influenza, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, and diabetes. Similarly, according to the CDC, mosquito-borne diseases (chikungunya, dengue, malaria, yellow fever, and Zika) are endemic in Brazil. Thus, the application of human vaccine adjuvants will increase due to the increasing disease burden in Brazil.
Rising healthcare expenditures and an increasing geriatric population are propelling the development of human vaccine adjuvants. According to the World Bank, Brazil's healthcare expenditure was 10.31% of the GDP in 2020, a significant increase from 8.91% in 2015. Additionally, the rising geriatric population in the country is at high risk for various diseases and disabilities. The OECD reported that 21.9% of the population in Brazil is expected to be 65 years and above by 2050, a significant increase from 8.9% in 2017. Thus, the increasing geriatric population, infectious disease prevalence, and health expenditure would propel the growth of Brazil's human vaccine adjuvants market in the coming years.South & Central America Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)South & Central America Human Vaccine Adjuvants Market SegmentationThe South & Central America human vaccine adjuvants market is categorized into type, application, end user, and country.
Based on type, the South & Central America human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.
In terms of application, the South & Central America human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.
By end user, the South & Central America human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.
By country, the South & Central America human vaccine adjuvants market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America human vaccine adjuvants market share in 2022.
Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp are some of the leading companies operating in the South & Central America human vaccine adjuvants market.
Reasons to BuySave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America human vaccine adjuvants market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America human vaccine adjuvants market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.